| Gene therapy: a pharmacokinetic/pharmacodynamic modelling overview ZP Parra-Guillén, G González-Aseguinolaza, P Berraondo, IF Trocóniz Pharmaceutical research 27 (8), 1487-1497, 2010 | 55 | 2010 |
| Review on modeling anti-antibody responses to monoclonal antibodies JD Gómez-Mantilla, IF Trocóniz, Z Parra-Guillén, MJ Garrido Journal of pharmacokinetics and pharmacodynamics 41 (5), 523-536, 2014 | 47 | 2014 |
| Pharmacometrics Markup Language (PharmML): opening new perspectives for model exchange in drug development MJ Swat, S Moodie, SM Wimalaratne, NR Kristensen, M Lavielle, A Mari, ... CPT: pharmacometrics & systems pharmacology 4 (6), 316-319, 2015 | 41 | 2015 |
| Pharmacokinetics and pharmacokinetic–pharmacodynamic relationships of monoclonal antibodies in children H Edlund, J Melin, ZP Parra-Guillen, C Kloft Clinical pharmacokinetics 54 (1), 35-80, 2015 | 36 | 2015 |
| Mathematical model approach to describe tumour response in mice after vaccine administration and its applicability to immune-stimulatory cytokine-based strategies ZP Parra-Guillen, P Berraondo, E Grenier, B Ribba, IF Troconiz The AAPS journal 15 (3), 797-807, 2013 | 32 | 2013 |
| The fusion protein of IFN-α and apolipoprotein AI crosses the blood–brain barrier by a saturable transport mechanism J Fioravanti, J Medina-Echeverz, N Ardaiz, C Gomar, ZP Parra-Guillén, ... The Journal of Immunology 188 (8), 3988-3992, 2012 | 29 | 2012 |
| Semimechanistic bone marrow exhaustion pharmacokinetic/pharmacodynamic model for chemotherapy-induced cumulative neutropenia A Henrich, M Joerger, S Kraff, U Jaehde, W Huisinga, C Kloft, ... Journal of Pharmacology and Experimental Therapeutics 362 (2), 347-358, 2017 | 28 | 2017 |
| Pharmacokinetic/pharmacodynamic evaluation of hydrocortisone therapy in pediatric patients with congenital adrenal hyperplasia J Melin, ZP Parra-Guillen, R Michelet, T Truong, W Huisinga, N Hartung, ... The Journal of Clinical Endocrinology & Metabolism 105 (4), e1729-e1740, 2020 | 25 | 2020 |
| Utilising the EGFR interactome to identify mechanisms of drug resistance in non-small cell lung cancer–Proof of concept towards a systems pharmacology approach H Saafan, S Foerster, ZP Parra-Guillen, E Hammer, M Michaelis, ... European journal of pharmaceutical sciences 94, 20-32, 2016 | 25 | 2016 |
| Modeling tumor response after combined administration of different immune-stimulatory agents ZP Parra-Guillen, P Berraondo, B Ribba, IF Trocóniz Journal of Pharmacology and Experimental Therapeutics 346 (3), 432-442, 2013 | 24 | 2013 |
| Exploiting pharmacokinetic models of tamoxifen and endoxifen to identify factors causing subtherapeutic concentrations in breast cancer patients L Klopp-Schulze, M Joerger, SG Wicha, R ter Heine, C Csajka, ... Clinical pharmacokinetics 57 (2), 229-242, 2018 | 22 | 2018 |
| Predicting Cortisol Exposure from Paediatric Hydrocortisone Formulation Using a Semi-Mechanistic Pharmacokinetic Model Established in Healthy Adults J Melin, ZP Parra-Guillen, N Hartung, W Huisinga, RJ Ross, MJ Whitaker, ... Clinical pharmacokinetics 57 (4), 515-527, 2018 | 21 | 2018 |
| Machine Learning Analysis of Individual Tumor Lesions in Four Metastatic Colorectal Cancer Clinical Studies: Linking Tumor Heterogeneity to Overall Survival D Vera-Yunca, P Girard, ZP Parra-Guillen, A Munafo, IF Trocóniz, ... The AAPS Journal 22 (3), 1-12, 2020 | 18 | 2020 |
| Role of cytochrome P450 3A4 and 1A2 phenotyping in patients with advanced non‐small‐cell lung cancer receiving erlotinib treatment ZP Parra‐Guillen, PB Berger, M Haschke, M Donzelli, D Winogradova, ... Basic & clinical pharmacology & toxicology 121 (4), 309-315, 2017 | 18 | 2017 |
| Paediatric population pharmacokinetic modelling to assess hydrocortisone replacement dosing regimens in young children R Michelet, J Melin, ZP Parra-Guillen, U Neumann, JM Whitaker, ... European Journal of Endocrinology 183 (4), 357-368, 2020 | 14 | 2020 |
| Population pharmacokinetic analysis of tiotropium in healthy volunteers after intravenous administration and inhalation Z Parra-Guillen, B Weber, A Sharma, J Freijer, S Retlich, JM Borghardt, ... J Pharmacokinet Pharmacodyn 41 (1), S54, 2014 | 14 | 2014 |
| Mechanistic Modeling of a Novel Oncolytic Virus, V937, to Describe Viral Kinetic and Dynamic Processes Following Intratumoral and Intravenous Administration ZP Parra-Guillen, T Freshwater, Y Cao, K Mayawala, S Zalba, MJ Garrido, ... Frontiers in Pharmacology 12, 705443, 2021 | 13 | 2021 |
| A Quantitative Systems Pharmacology model for the key Interleukins involved in Crohn's Disease V Balbas-Martinez, E Asin-Prieto, ZP Parra-Guillen, IF Troconiz Journal of Pharmacology and Experimental Therapeutics 372 (3), 299-307, 2020 | 12 | 2020 |
| Systematic modeling and design evaluation of unperturbed tumor dynamics in xenografts ZP Parra-Guillen, V Mangas-Sanjuan, M Garcia-Cremades, IF Troconiz, ... Journal of Pharmacology and Experimental Therapeutics 366 (1), 96-104, 2018 | 12 | 2018 |
| Model description language (MDL): a standard for modeling and simulation MK Smith, SL Moodie, R Bizzotto, E Blaudez, E Borella, L Carrara, ... CPT: pharmacometrics & systems pharmacology 6 (10), 647-650, 2017 | 12 | 2017 |
Iñaki TrocónizUniversidad de NavarraVerified email at unav.es
Iñaki TrocónizUniversidad de NavarraVerified email at unav.es